Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

valent biosciences a div of sumitomo chemical australia - gibberellic acid - water soluble granules - gibberellic acid plant growth regulator active 400.0 g/kg - growth regulator - cherry | grape - currant (dried fruit) | grape - early madeleine | grape - flame seedless | grape - perlette | grape - sultana | - improve berry set | improve fruit development | improve fruit quality | increase bunch size | promote desirable harvest effects | reduction in severity of creasing | stimulate production | growth stimulation | rapid plant growth | to achieve berry thinning | to achieve bunch elongation (s | to achieve increase in berry s | to delay rind ageing | to improve storage life | to reduce rind blemish

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 90 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 60 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 45 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 30 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 15 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; indigo carmine aluminium lake; magnesium stearate - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with chronic kidney disease (ckd) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (see pharmacology).

Singapore - English - HSA (Health Sciences Authority)

equip medical pte ltd - general & plastic surgery - it is intended for vacuum extraction, aspiration and removal of surgical fluids, tissue (including bone), gases, bodily fluids or infectious materials from wounds or from a patient's airway or respiratory support system, either during surgery or at the patient’s bedside.

Australia - English - Department of Health (Therapeutic Goods Administration)

dominant (australia) pty ltd -

Israel - English - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.